Transplant Registries: Guiding Clinical Decisions and Improving Outcomes
About 50,000 hematopoietic stem cell transplantations are performed yearly, primarily for malignancies. Use of this therapy increased dramatically over the past 30 years due to its proven and potential efficacy in diverse
ABSTRACT: About 50,000 hematopoietic stem cell transplantations areperformed yearly, primarily for malignancies. Use of this therapy increaseddramatically over the past 30 years due to its proven and potential efficacy indiverse diseases, better understanding of appropriate timing of transplantationand patient selection, and greater availability of allogeneic donors. TheInternational Bone Marrow Transplant Registry (IBMTR) and the Autologous Bloodand Marrow Transplant Registry (ABMTR) collect data on consecutive allogeneicand autologous transplants, respectively, in more than 400 participating centersworldwide. The IBMTR/ABMTR database contains information on more than 120,000transplant recipients. Among 11,347 patients transplanted in 101 IBMTR/ABMTRresearch centers in North America during 1995-1997, 66% received autologoustransplants, 24% related-donor transplants, and 10% unrelated-donor transplants.More than 90% of transplantations were for malignant disease, with more thanhalf of these done in patients with advanced disease. Of the recipients, 70%were younger than 50 years. Posttransplant survivals varied substantially bydisease, transplant type, recipient age, and disease status at transplantation.IBMTR/ABMTR data provide an important tool for assessing transplant use andoutcome, identifying prognostic factors for transplant outcomes, evaluating newtransplant therapies, comparing transplant and nontransplant therapies,evaluating late transplant complications, and planning prospective phase II andIII clinical trials. [ONCOLOGY 15(5):649-666, 2001]
Internal server error